NASDAQ:NBRV

Nabriva Therapeutics Competitors

$1.47
+0.02 (+1.38 %)
(As of 04/14/2021 03:01 PM ET)
Add
Compare
Today's Range
$1.44
Now: $1.47
$1.54
50-Day Range
$1.56
MA: $1.90
$2.80
52-Week Range
$1.42
Now: $1.47
$12.00
Volume20,195 shs
Average Volume2.10 million shs
Market Capitalization$367.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.91

Competitors

Nabriva Therapeutics (NASDAQ:NBRV) Vs. SAVA, AMTI, GBIO, ZEAL, ATBPD, and ENDP

Should you be buying NBRV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Nabriva Therapeutics, including Cassava Sciences (SAVA), Applied Molecular Transport (AMTI), Generation Bio (GBIO), Zealand Pharma A/S (ZEAL), Antibe Therapeutics (ATBPD), and Endo International (ENDP).

Cassava Sciences (NASDAQ:SAVA) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Cassava Sciences and Nabriva Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cassava SciencesN/A-22.01%-20.85%
Nabriva Therapeutics-1,682.55%-129.80%-71.67%

Analyst Ratings

This is a summary of current recommendations for Cassava Sciences and Nabriva Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cassava Sciences00403.00
Nabriva Therapeutics01102.50

Cassava Sciences currently has a consensus target price of $35.3333, indicating a potential downside of 1.99%. Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Cassava Sciences.

Institutional and Insider Ownership

26.7% of Cassava Sciences shares are owned by institutional investors. Comparatively, 23.7% of Nabriva Therapeutics shares are owned by institutional investors. 13.7% of Cassava Sciences shares are owned by company insiders. Comparatively, 2.8% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Cassava Sciences and Nabriva Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-131.26
Nabriva Therapeutics$9.48 million38.80$-82,760,000.00($11.20)-0.13

Cassava Sciences has higher earnings, but lower revenue than Nabriva Therapeutics. Cassava Sciences is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cassava Sciences has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500.

Summary

Cassava Sciences beats Nabriva Therapeutics on 9 of the 13 factors compared between the two stocks.

Applied Molecular Transport (NASDAQ:AMTI) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Applied Molecular Transport and Nabriva Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied Molecular TransportN/AN/AN/A
Nabriva Therapeutics-1,682.55%-129.80%-71.67%

Analyst Ratings

This is a summary of current recommendations for Applied Molecular Transport and Nabriva Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Molecular Transport00403.00
Nabriva Therapeutics01102.50

Applied Molecular Transport currently has a consensus target price of $68.75, indicating a potential upside of 62.61%. Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Applied Molecular Transport.

Institutional and Insider Ownership

52.0% of Applied Molecular Transport shares are owned by institutional investors. Comparatively, 23.7% of Nabriva Therapeutics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Applied Molecular Transport and Nabriva Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A
Nabriva Therapeutics$9.48 million38.80$-82,760,000.00($11.20)-0.13

Applied Molecular Transport has higher earnings, but lower revenue than Nabriva Therapeutics.

Summary

Applied Molecular Transport beats Nabriva Therapeutics on 7 of the 10 factors compared between the two stocks.

Generation Bio (NASDAQ:GBIO) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Generation Bio and Nabriva Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Generation BioN/AN/AN/A
Nabriva Therapeutics-1,682.55%-129.80%-71.67%

Analyst Ratings

This is a summary of current recommendations for Generation Bio and Nabriva Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Generation Bio00603.00
Nabriva Therapeutics01102.50

Generation Bio currently has a consensus target price of $40.60, indicating a potential upside of 52.46%. Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Generation Bio.

Institutional and Insider Ownership

63.3% of Generation Bio shares are owned by institutional investors. Comparatively, 23.7% of Nabriva Therapeutics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Generation Bio and Nabriva Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation BioN/AN/AN/AN/AN/A
Nabriva Therapeutics$9.48 million38.80$-82,760,000.00($11.20)-0.13

Generation Bio has higher earnings, but lower revenue than Nabriva Therapeutics.

Summary

Generation Bio beats Nabriva Therapeutics on 6 of the 9 factors compared between the two stocks.

Zealand Pharma A/S (NASDAQ:ZEAL) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Zealand Pharma A/S and Nabriva Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zealand Pharma A/S$6.20 million229.53$-85,670,000.00($2.54)-12.91
Nabriva Therapeutics$9.48 million38.80$-82,760,000.00($11.20)-0.13

Nabriva Therapeutics has higher revenue and earnings than Zealand Pharma A/S. Zealand Pharma A/S is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

4.3% of Zealand Pharma A/S shares are owned by institutional investors. Comparatively, 23.7% of Nabriva Therapeutics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zealand Pharma A/S and Nabriva Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zealand Pharma A/S-214.31%-38.34%-30.40%
Nabriva Therapeutics-1,682.55%-129.80%-71.67%

Analyst Ratings

This is a summary of current recommendations for Zealand Pharma A/S and Nabriva Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zealand Pharma A/S00203.00
Nabriva Therapeutics01102.50

Zealand Pharma A/S currently has a consensus target price of $43.00, indicating a potential upside of 31.14%. Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Zealand Pharma A/S.

Risk & Volatility

Zealand Pharma A/S has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500.

Antibe Therapeutics (NASDAQ:ATBPD) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Antibe Therapeutics and Nabriva Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe Therapeutics$7.51 million188.60$-14,540,000.00($0.50)-7.32
Nabriva Therapeutics$9.48 million38.80$-82,760,000.00($11.20)-0.13

Antibe Therapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

23.7% of Nabriva Therapeutics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Antibe Therapeutics and Nabriva Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antibe Therapeutics-273.96%-176.23%-106.91%
Nabriva Therapeutics-1,682.55%-129.80%-71.67%

Analyst Recommendations

This is a breakdown of recent ratings for Antibe Therapeutics and Nabriva Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antibe Therapeutics0000N/A
Nabriva Therapeutics01102.50

Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Antibe Therapeutics.

Volatility and Risk

Antibe Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.

Summary

Nabriva Therapeutics beats Antibe Therapeutics on 9 of the 13 factors compared between the two stocks.

Endo International (NASDAQ:ENDP) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Endo International and Nabriva Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Endo International$2.91 billion0.49$-422,640,000.00$2.382.61
Nabriva Therapeutics$9.48 million38.80$-82,760,000.00($11.20)-0.13

Nabriva Therapeutics has lower revenue, but higher earnings than Endo International. Nabriva Therapeutics is trading at a lower price-to-earnings ratio than Endo International, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

80.0% of Endo International shares are owned by institutional investors. Comparatively, 23.7% of Nabriva Therapeutics shares are owned by institutional investors. 1.5% of Endo International shares are owned by insiders. Comparatively, 2.8% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Endo International and Nabriva Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Endo International-5.30%-85.80%7.19%
Nabriva Therapeutics-1,682.55%-129.80%-71.67%

Analyst Recommendations

This is a breakdown of recent ratings for Endo International and Nabriva Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Endo International23302.13
Nabriva Therapeutics01102.50

Endo International presently has a consensus target price of $7.6667, indicating a potential upside of 22.47%. Nabriva Therapeutics has a consensus target price of $6.00, indicating a potential upside of 294.74%. Given Nabriva Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nabriva Therapeutics is more favorable than Endo International.

Volatility and Risk

Endo International has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.


Nabriva Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$35.44+1.7%$1.44 billionN/A-147.67Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.49+2.0%$1.43 billionN/A0.00Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$26.32+3.5%$1.43 billionN/A0.00Increase in Short Interest
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.79+2.1%$1.42 billion$6.20 million-14.38
ATBPD
Antibe Therapeutics
0.1$3.66+0.0%$1.42 billion$7.51 million-6.10Gap Down
Endo International logo
ENDP
Endo International
1.3$6.21+1.6%$1.41 billion$2.91 billion-9.13
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$28.08+1.0%$1.39 billionN/A-3.04Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.13+2.3%$1.37 billion$19.89 million-13.27
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.81+4.9%$1.37 billion$4.23 million-20.60Increase in Short Interest
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.27+3.2%$1.34 billion$73.41 million-4.50Unusual Options Activity
News Coverage
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.5$33.28+3.5%$1.34 billionN/A0.00Analyst Report
Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.90+1.3%$1.33 billionN/A0.00Analyst Upgrade
OLMA
Olema Pharmaceuticals
1.6$35.46+8.4%$1.30 billionN/A0.00Increase in Short Interest
Zymeworks logo
ZYME
Zymeworks
1.8$30.02+7.0%$1.29 billion$29.54 million-7.96News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$22.55+1.5%$1.28 billionN/A0.00Insider Selling
Unusual Options Activity
Gap Down
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.39+1.5%$1.22 billionN/A-2.75Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.10+3.0%$1.21 billionN/A-18.94
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.43+3.3%$1.21 billion$4.23 million-9.18News Coverage
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.91+4.3%$1.20 billionN/A0.00
Innoviva logo
INVA
Innoviva
1.4$11.68+0.4%$1.18 billion$261.02 million5.96
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$25.18+20.6%$1.17 billionN/A0.00Increase in Short Interest
Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.32+0.4%$1.17 billion$59.70 million-193.20
NKTX
Nkarta
1.8$35.71+0.5%$1.17 billionN/A0.00Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.16+2.0%$1.13 billion$35.22 million-7.42
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$25.65+0.3%$1.12 billion$230,000.00-11.93News Coverage
Gap Down
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.94+4.6%$1.12 billion$42.12 million-12.55Unusual Options Activity
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.60+3.8%$1.11 billionN/A-8.96Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$17.79+1.7%$1.08 billion$111.81 million-7.47
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.24+0.1%$1.08 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.15+2.8%$1.07 billionN/A-6.81
Zogenix logo
ZGNX
Zogenix
1.7$19.45+1.9%$1.06 billion$3.65 million-2.05
MannKind logo
MNKD
MannKind
1.4$4.46+5.6%$1.05 billion$63.04 million-21.24Increase in Short Interest
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$23.00+4.8%$1.05 billionN/A-8.49Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.15+0.7%$1.04 billion$120,000.00-3.76Analyst Upgrade
News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$39.73+0.7%$1.04 billion$20.79 million-13.70Analyst Upgrade
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$20.92+1.3%$1.04 billionN/A-6.88Increase in Short Interest
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$24.75+1.9%$1.02 billionN/A-8.53
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.37+1.9%$996.70 million$122.47 million-27.68Analyst Downgrade
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$21.71+5.1%$993.66 million$1.52 million-11.55Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.17+0.5%$982.60 million$800.40 million22.80
Prothena logo
PRTA
Prothena
2.1$23.66+1.2%$934.94 million$810,000.00-9.24Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$26.96+2.0%$918.28 millionN/A-12.42Analyst Upgrade
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$26.75+1.2%$914.76 millionN/A-24.77
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.59+1.7%$895.14 million$227.19 million46.08
Radius Health logo
RDUS
Radius Health
1.1$19.48+3.0%$886.30 million$173.32 million-7.98Gap Down
Annexon logo
ANNX
Annexon
1.9$23.35+1.3%$879.54 millionN/A0.00Increase in Short Interest
Gap Down
Affimed logo
AFMD
Affimed
1.6$10.31+4.1%$873.54 million$23.96 million-17.47Analyst Report
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.39+2.8%$869.64 millionN/A0.00News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.20+2.4%$863.20 million$31.13 million-7.56Analyst Report
Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.00+1.7%$845.56 millionN/A-10.39
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.